Citation: Makhloufi Zoulikha, Zhongjian Chen, Jun Wu, Wei He. Approved delivery strategies for biopharmaceuticals[J]. Chinese Chemical Letters, ;2025, 36(2): 110225. doi: 10.1016/j.cclet.2024.110225 shu

Approved delivery strategies for biopharmaceuticals

Makhloufi Zoulikha ^a ,
Zhongjian Chen ^{b, *,} ,
Jun Wu ^{c, *,} ,
Wei He ^{b, *,}

a.
School of Pharmacy, China Pharmaceutical University, Nanjing 2111198, China
b.
Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China
c.
Department of Geriatric Cardiology, Jiangsu Provincial Key Laboratory of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

aajian818@163.com

wujun9989@njmu.edu.cn

weihe@cpu.edu.cn

Received Date: 10 April 2024
Revised Date: 3 July 2024
Accepted Date: 7 July 2024
Available Online: 8 July 2024

Figures(2)

In recent years, biopharmaceuticals have witnessed remarkable advancements, transforming the landscape of therapeutic interventions. Biopharmaceuticals encompassing therapeutics generated through cutting-edge biotechnological methods have shown promising therapeutic outcomes. However, their clinical success hinges significantly on overcoming drug delivery challenges related to stability, intracellular delivery, immunogenicity, and pharmacokinetic properties. Herein, we provide an overview of various marketed macromolecules, including nucleic acids, and immunotherapeutic agents such as cytokines and monoclonal antibodies, as well as other therapeutic peptides/proteins like enzymes, hormones, and coagulation factors. Our primary focus is on elucidating the delivery challenges associated with these macromolecules and highlighting the pivotal role played by drug delivery platforms in the development of currently marketed products, offering valuable insights for both scientific research and the pharmaceutical industry.
- Biopharmaceuticals,
- Nucleic acids,
- Monoclonal antibodies,
- Proteins,
- Drug delivery
1. [1]
  T. Reynolds, C. de Zafra, A. Kim, T.R. Gelzleichter, Overview of biopharmaceuticals and comparison with small-molecule drug development, in: L.M. Plitnick, D.J. Herzyk (Eds.), Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics, Academic Press, London, 2013, pp. 3–33.
2. [2]
  F. Hu, J. Qi, Y. Lu, H. He, W. Wu, Chin. Chem. Lett. 34 (2023) 108250. doi: 10.1016/j.cclet.2023.108250
3. [3]
  A.C. Szkodny, K.H. Lee, Annu. Rev. Chem. Biomol. Eng. 13 (2022) 141–165. doi: 10.1146/annurev-chembioeng-092220-125832
4. [4]
  D. Feng, L. Liu, Y. Shi, et al., Chin. Chem. Lett. 34 (2023) 108026. doi: 10.1016/j.cclet.2022.108026
5. [5]
  M. Durán-Lobato, A.M. López-Estévez, A.S. Cordeiro, et al., Adv. Drug Deliv. Rev. 176 (2021) 113899. doi: 10.1016/j.addr.2021.113899
6. [6]
  K. Thapa Magar, G.F. Boafo, X. Li, Z. Chen, W. He, Chin. Chem. Lett. 33 (2022) 587–596. doi: 10.1016/j.cclet.2021.08.020
7. [7]
  R.A. Rader, Nat. Biotechnol. 26 (2008) 743–751. doi: 10.1038/nbt0708-743
8. [8]
  T.T.K. Nguyen, K.Y. Pham, S. Yook, Acta Biomater. 171 (2023) 131–154. doi: 10.1016/j.actbio.2023.09.018
9. [9]
  X. Pan, H. Veroniaina, N. Su, et al., Asian J. Pharm. Sci. 16 (2021) 687. doi: 10.1016/j.ajps.2021.05.003
10. [10]
  Y. Zhu, L. Zhu, X. Wang, H. Jin, Cell Death Dis. 13 (2022) 644. doi: 10.3390/machines10080644
11. [11]
  K. Sridharan, N.J. Gogtay, Br. J. Clin. Pharmacol. 82 (2016) 659. doi: 10.1111/bcp.12987
12. [12]
  T.C. Roberts, R. Langer, M.J.A.A. Wood, Nat. Rev. Drug Discov. 19 (2020) 673–694. doi: 10.1038/s41573-020-0075-7
13. [13]
  B.B. Mendes, J. Conniot, A. Avital, et al., Nat. Rev. Methods Prim. 2 (2022) 24. doi: 10.1038/s43586-022-00104-y
14. [14]
  R. Liu, C. Luo, Z. Pang, et al., Chin. Chem. Lett. 34 (2023) 107518. doi: 10.1016/j.cclet.2022.05.032
15. [15]
  X. Li, X. Peng, M. Zoulikha, et al., Signal Transduct. Target. Ther. 9 (2024) 1. doi: 10.1038/s41392-023-01668-1
16. [16]
  W. Zhang, Y. Jiang, Y. He, et al., Acta Pharm. Sin. B 13 (2023) 4105–4126. doi: 10.1016/j.apsb.2022.11.026
17. [17]
  Y.A. Heo, Drugs 83 (2023) 347–352. doi: 10.1007/s40265-023-01845-0
18. [18]
  A. Lee, Drugs 83 (2023) 353. doi: 10.1007/s40265-023-01846-z
19. [19]
  H.A. Blair, Drugs 82 (2022) 1505–1510. doi: 10.1007/s40265-022-01788-y
20. [20]
  S.M. Hoy, Drugs 83 (2023) 1323–1329. doi: 10.1007/s40265-023-01929-x
21. [21]
  I. Lostalé-Seijo, J. Montenegro, Nat. Rev. Chem. 2 (2018) 258–277. doi: 10.1038/s41570-018-0039-1
22. [22]
  A.M. Vargason, A.C. Anselmo, S. Mitragotri, Nat. Biomed. Eng. 5 (2021) 951–967. doi: 10.1038/s41551-021-00698-w
23. [23]
  K. Lundstrom, Viruses 15 (2023) 698. doi: 10.3390/v15030698
24. [24]
  S.S. Issa, A.A. Shaimardanova, V.V. Solovyeva, A.A. Rizvanov, Cells 12 (2023) 785. doi: 10.3390/cells12050785
25. [25]
  M. Senior, Nat. Biotechnol. 35 (2017) 491–492. doi: 10.1038/nbt0617-491
26. [26]
  FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. https://www.fda.gov/newsevents/pressannouncements/fdaapprovesnovelgenetherapytreatpatientsrareforminheritedvisionloss, 2017.
27. [27]
  H.A. Blair, CNS Drugs 36 (2022) 995–1005. doi: 10.1007/s40263-022-00941-1
28. [28]
  M.C. Ozelo, J. Mahlangu, K.J. Pasi, et al., N. Engl. J. Med. 386 (2022) 1013–1025. doi: 10.1056/nejmoa2113708
29. [29]
  N. Mukherjee, R.S. Svatek, A.M. Mansour, Urol. Oncol. 36 (2018) 103–108. doi: 10.1016/j.urolonc.2017.12.020
30. [30]
  C.M. Zaidman, C.M. Proud, C.M. McDonald, et al., Ann. Neurol. 94 (2023) 955–968. doi: 10.1002/ana.26755
31. [31]
  N.L. Goedeker, S.D. Dharia, D.A. Griffin, et al., Ther. Adv. Neurol. Disord. 16 (2023) 17562864221149781. doi: 10.1177/17562864221149781
32. [32]
  G. Kara, G.A. Calin, B. Ozpolat, Adv. Drug Deliv. Rev. 182 (2022) 114113. doi: 10.1016/j.addr.2022.114113
33. [33]
  N.D. Germain, W.K. Chung, P.D. Sarmiere, Mol. Aspects Med. 91 (2023) 101148. doi: 10.1016/j.mam.2022.101148
34. [34]
  M.A. Subhan, V.P. Torchilin, Transl. Res. 214 (2019) 62–91. doi: 10.1016/j.trsl.2019.07.006
35. [35]
  N. Dammes, D. Peer, Trends Pharmacol. Sci. 41 (2020) 755–775. doi: 10.1016/j.tips.2020.08.004
36. [36]
  K. Paunovska, D. Loughrey, J.E. Dahlman, Nat. Rev. Genet. 23 (2022) 265–280. doi: 10.1038/s41576-021-00439-4
37. [37]
  S.M. Hoy, Drugs 78 (2018) 1625–1631. doi: 10.1007/s40265-018-0983-6
38. [38]
  Y.N. Lamb, Drugs 81 (2021) 495–501. doi: 10.1007/s40265-021-01480-7
39. [39]
  L.R. Baden, H.M. El Sahly, B. Essink, et al., N. Engl. J. Med. 384 (2021) 403–416. doi: 10.1056/nejmoa2035389
40. [40]
  L.J. Scott, Drugs 80 (2020) 335–339. doi: 10.1007/s40265-020-01269-0
41. [41]
  X. Gang, F. Liu, J. Mao, Front. Pediatr. 10 (2023) 1052625. doi: 10.3389/fped.2022.1052625
42. [42]
  Y.N. Lamb, Drugs 81 (2021) 389–395. doi: 10.1007/s40265-021-01473-6
43. [43]
  S.J. Keam, Drugs 82 (2022) 1419–1425. doi: 10.1007/s40265-022-01765-5
44. [44]
  Y.Y. Syed, Drugs 83 (2023) 1729–1733. doi: 10.1007/s40265-023-01976-4
45. [45]
  F. Gao, J. Yin, Y. Chen, et al., Front. Bioeng. Biotechnol. 10 (2022) 972933. doi: 10.3389/fbioe.2022.972933
46. [46]
  C. Kang, Drugs 83 (2023) 1447–1453. doi: 10.1007/s40265-023-01948-8
47. [47]
  M.M. Zhang, R. Bahal, T.P. Rasmussen, et al., Biochem. Pharmacol. 189 (2021) 114432. doi: 10.1016/j.bcp.2021.114432
48. [48]
  S.C. Semple, R. Leone, C.J. Barbosa, et al., Pharmaceutics 14 (2022) 398. doi: 10.3390/pharmaceutics14020398
49. [49]
  Y. Suzuki, H. Ishihara, Drug Metab. Pharmacokinet. 41 (2021) 100424. doi: 10.1016/j.dmpk.2021.100424
50. [50]
  M. Zoulikha, Q. Xiao, G.F. Boafo, et al., Acta Pharm. Sin. B 12 (2022) 600–620. doi: 10.1016/j.apsb.2021.08.009
51. [51]
  L. Zhang, Y. Liang, G. Liang, et al., Front. Pharmacol. 13 (2022) 1090237. doi: 10.3389/fphar.2022.1090237
52. [52]
  A.D. Springer, S.F. Dowdy, Nucleic Acid Ther. 28 (2018) 109–118. doi: 10.1089/nat.2018.0736
53. [53]
  S. Qin, X. Tang, Y. Chen, et al., Signal Transduct. Target. Ther. 7 (2022) 166. doi: 10.1038/s41392-022-01007-w
54. [54]
  K. Leppek, G.W. Byeon, W. Kladwang, et al., Nat. Commun. 13 (2022) 1536. doi: 10.1038/s41467-022-28776-w
55. [55]
  J.Wei Nitika, A.M. Hui, Life 12 (2022) 1254. doi: 10.3390/life12081254
56. [56]
  C. Webb, S. Ip, N.V. Bathula, et al., Mol. Pharm. 19 (2022) 1047–1058. doi: 10.1021/acs.molpharmaceut.2c00010
57. [57]
  S. Ni, Z. Zhuo, Y. Pan, et al., ACS Appl. Mater. Interfaces 13 (2021) 9500–9519. doi: 10.1021/acsami.0c05750
58. [58]
  P. Chen, C. Yu, J. Chen, L. Xu, H. Liu, Chin. Chem. Lett. 34 (2023) 108627. doi: 10.1016/j.cclet.2023.108627
59. [59]
  H. Park, A. Otte, K. Park, J. Control. Release 342 (2022) 53–65. doi: 10.1016/j.jconrel.2021.12.030
60. [60]
  M. Li, W. Zhang, J. Li, et al., Chin. Chem. Lett. 34 (2023) 108177. doi: 10.1016/j.cclet.2023.108177
61. [61]
  L. Zhou, M. Zou, Y. Xu, et al., Front. Oncol. 12 (2022) 864301. doi: 10.3389/fonc.2022.864301
62. [62]
  Q. Xiao, X. Li, Y. Li, et al., Acta Pharm. Sin. B 11 (2021) 941. doi: 10.1016/j.apsb.2020.12.018
63. [63]
  M.S. Goldberg, Nat. Rev. Cancer 19 (2019) 587–602. doi: 10.1038/s41568-019-0186-9
64. [64]
  P. Berraondo, M.F. Sanmamed, M.C. Ochoa, et al., Br. J. Cancer 120 (2018) 6–15.
65. [65]
  R.S. Riley, C.H. June, R. Langer, et al., Nat. Rev. Drug Discov. 18 (2019) 175–196. doi: 10.1038/s41573-018-0006-z
66. [66]
  I.S. Pires, P.T. Hammond, D.J. Irvine, Adv. Ther. 4 (2021) 2100035. doi: 10.1002/adtp.202100035
67. [67]
  A. Gonçalves, R. Machado, A.C. Gomes, Appl. Sci. 10 (2020) 7098. doi: 10.3390/app10207098
68. [68]
  Y.Sen Wang, S. Youngster, M. Grace, et al., Adv. Drug Deliv. Rev. 54 (2002) 547–570. doi: 10.1016/S0169-409X(02)00027-3
69. [69]
  K. Rajender Reddy, M.W. Modi, S. Pedder, Adv. Drug Deliv. Rev. 54 (2002) 571–586. doi: 10.1016/S0169-409X(02)00028-5
70. [70]
  S.M. Hoy, CNS Drugs 29 (2015) 171–179. doi: 10.1007/s40263-015-0227-1
71. [71]
  S.J. Hsu, M.L. Yu, C.W. Su, et al., J. Formos. Med. Assoc. 120 (2021) 956–964. doi: 10.1016/j.jfma.2020.09.018
72. [72]
  D.M. Piedmonte, M.J. Treuheit, Adv. Drug Deliv. Rev. 60 (2008) 50–58. doi: 10.1016/j.addr.2007.04.017
73. [73]
  L.S. Schwartzberg, G. Bhat, J. Peguero, et al., Oncologist 25 (2020) e1233. doi: 10.1634/theoncologist.2020-0105
74. [74]
  J. Hoggatt, T.A. Tate, L.M. Pelus, Int. J. Nanomed. 10 (2015) 10–2647.
75. [75]
  L. McGahan, Issues Emerg. Health Technol. 113 (2008) 1–6.
76. [76]
  Z. Wang, J. Huang, D. Xie, D. He, A. Lu, C. Liang, Front. Immunol. 12 (2021) 755844. doi: 10.3389/fimmu.2021.755844
77. [77]
  M. Abdeladhim, J.L. Karnell, S.A. Rieder, Front. Immunol. 13 (2022), doi: 10.3389/fimmu.2022.1033705. doi: 10.3389/fimmu.2022.1033705
78. [78]
  E. El-Charabaty, A.S. Geara, C. Ting, S. El-Sayegh, J. Azzi, Expert Rev. Clin. Immunol. 8 (2012) 527–536. doi: 10.1586/eci.12.42
79. [79]
  E.A. Dubois, R. Rissmann, A.F. Cohen, Br. J. Clin. Pharmacol. 71 (2011) 639. doi: 10.1111/j.1365-2125.2011.03958.x
80. [80]
  M.W. Stewart, Br. J. Ophthalmol. 96 (2012) 1157. doi: 10.1136/bjophthalmol-2011-300654
81. [81]
  J.R. de Oliveira Dias, G.C. de Andrade, E.A. Novais, M.E. Farah, E.B. Rodrigues, Int. J. Retina Vitreous 2 (2016) 3. doi: 10.1186/s40942-016-0026-y
82. [82]
  S. Zalipsky, G. Pasut, Evolution of polymer conjugation to proteins, in: G. Pasut, S. Zalipsky (Eds.), Polymer-protein Conjugates, Elsevier, Amsterdam, 2020, pp. 3–22.
83. [83]
  K.Y. Chen, K.Y. Lee, A. Qin, et al., Adv. Ther. 39 (2022) 910. doi: 10.1007/s12325-021-01998-y
84. [84]
  V. Gadekar, Y. Borade, S. Kannaujia, et al., J. Control. Release 330 (2021) 372–397. doi: 10.1016/j.jconrel.2020.12.034
85. [85]
  G. Reynaldo, L. Rodríguez, R. Menéndez, et al., J. Pharm. Pharmacogn. Res. 6 (2018) 179. doi: 10.56499/jppres17.342_6.3.179
86. [86]
  J. Dholakia, A.C. Cohen, C.A. Leath, et al., Curr. Oncol. Rep. 24 (2022) 389–397. doi: 10.1007/s11912-022-01221-3
87. [87]
  J. Zhao, G. Hu, Y. Huang, Y. Huang, X. Wei, J. Shi, Chin. Chem. Lett. 32 (2021) 1331–1340. doi: 10.1016/j.cclet.2020.10.013
88. [88]
  D.R. Goulet, W.M. Atkins, J. Pharm. Sci. 109 (2020) 74–103. doi: 10.1016/j.xphs.2019.05.031
89. [89]
  W. He, X. Xing, X. Wang, et al., Adv. Funct. Mater. 30 (2020) 1910566. doi: 10.1002/adfm.201910566
90. [90]
  J.K. Dozier, M.D. Distefano, Int. J. Mol. Sci. 16 (2015) 25831–25864. doi: 10.3390/ijms161025831
91. [91]
  S. Baah, M. Laws, K.M. Rahman, Molecules 26 (2021) 2943. doi: 10.3390/molecules26102943
92. [92]
  R. Sheyi, B.G. de la Torre, F. Albericio, Pharmaceutics 14 (2022) 396. doi: 10.3390/pharmaceutics14020396
93. [93]
  Z. Fu, S. Li, S. Han, C. Shi, Y. Zhang, Signal Transduct. Target. Ther. 7 (2022) 93. doi: 10.1038/s41392-022-00947-7
94. [94]
  H. Jiang, W. Chen, J. Wang, R. Zhang, Chin. Chem. Lett. 33 (2022) 80–88. doi: 10.1016/j.cclet.2021.06.011
95. [95]
  H. Singh, V.J. Leyton, Mol. Cancer Ther. 20 (2021) P062. doi: 10.1158/1535-7163.targ-21-p062
96. [96]
  J. Chen, H. Xue, Q. Chen, Y. Lin, D. Tang, J. Zheng, Chin. Chem. Lett. 30 (2019) 1631–1634. doi: 10.1016/j.cclet.2019.03.045
97. [97]
  F. Riccardi, M. Dal Bo, P. Macor, G. Toffoli, Front. Pharmacol. 14 (2023) 1274088. doi: 10.3389/fphar.2023.1274088
98. [98]
  C. Dumontet, J.M. Reichert, P.D. Senter, J.M. Lambert, A. Beck, Nat. Rev. Drug Discov. 22 (2023) 641–661. doi: 10.1038/s41573-023-00709-2
99. [99]
  J.M. Sasso, R. Tenchov, R. Bird, et al., Bioconjug. Chem. 34 (2023) 1951–2000. doi: 10.1021/acs.bioconjchem.3c00374
100. [100]
  M.C. Marsh, S.C. Owen, AAPS J. 26 (2023) 3. doi: 10.1208/s12248-023-00873-8
101. [101]
  Z. Guo, Y. Liu, N. He, Y. Deng, L. Jin, Chin. Chem. Lett. 32 (2021) 40–47. doi: 10.1016/j.cclet.2020.11.061
102. [102]
  B. Li, C. Teng, H. Yu, X. Jiang, et al., Acta Pharm. Sin. B 13 (2023) 2369–2382. doi: 10.1016/j.apsb.2022.12.002
103. [103]
  Q. Xiao, X. Li, C. Liu, et al., Acta Pharm. Sin. B 13 (2023) 3503–3517. doi: 10.1016/j.apsb.2022.07.012
104. [104]
  M.J. Dorsey, A. Rubinstein, H. Lehman, et al., J. Clin. Immunol. 43 (2023) 951–964. doi: 10.1007/s10875-022-01426-y
105. [105]
  L. Murguia-Favela, W. Min, R. Loves, M. Leon-Ponte, E. Grunebaum, Clin. Exp. Immunol. 200 (2020) 176–184. doi: 10.1111/cei.13420
106. [106]
  P.A. Dinndorf, J. Gootenberg, M.H. Cohen, P. Keegan, R. Pazdur, Oncologist 12 (2007) 991–998. doi: 10.1634/theoncologist.12-8-991
107. [107]
  R.J. Li, R. Jin, C. Liu, et al., Clin. Cancer Res. 26 (2020) 328–331. doi: 10.1158/1078-0432.ccr-19-1255
108. [108]
  P.E. Lipsky, L.H. Calabrese, A. Kavanaugh, et al., Arthritis Res. Ther. 16 (2014) R60. doi: 10.1186/ar4497
109. [109]
  A. Markham, BioDrugs 32 (2018) 391–395. doi: 10.1007/s40259-018-0292-3
110. [110]
  M. Lenders, L.M. Feidicker, S.-M. Brand, E. Brand, Front. Immunol. 14 (2023) 1266082. doi: 10.3389/fimmu.2023.1266082
111. [111]
  O.S. Strandbech, A. Lund, E. Ostergaard, IMD Rep. 59 (2021) 10–15. doi: 10.1002/jmd2.12198
112. [112]
  Y. Wang, M. Kim, C. Buckley, H.D. Maynard, R.J. Langley, J.K. Perry, Protein Sci. 32 (2023) e4727. doi: 10.1002/pro.4727
113. [113]
  M. Steiner, J. Frank, P. Saenger, Pediatr. Investig. 7 (2023) 36–42. doi: 10.1002/ped4.12358
114. [114]
  L. Sävendahl, T. Battelino, M. Højby Rasmussen, et al., J. Clin. Endocrinol. Metab. 107 (2022) 1357. doi: 10.1210/clinem/dgab928
115. [115]
  Y. Gao, M. Joshi, Z. Zhao, S. Mitragotri, J.A. Paulson, Bioeng. Transl. Med. 9 (2024) e10600. doi: 10.1002/btm2.10600
116. [116]
  J. Paik, E.D. Deeks, Drugs 79 (2019) 1147–1156. doi: 10.1007/s40265-019-01152-7
117. [117]
  L. Zou, M. Cheng, K. Hu, J. Feng, L. Tu, Chin. Chem. Lett. 35 (2024) 109129. doi: 10.1016/j.cclet.2023.109129
118. [118]
  Y.Y. Syed, Drugs 77 (2017) 2003–2012. doi: 10.1007/s40265-017-0836-8
119. [119]
  J.E. Frampton, Drugs 81 (2021) 2035–2046. doi: 10.1007/s40265-021-01615-w
120. [120]
  S.J. Keam, Drugs 83 (2023) 633–638. doi: 10.1007/s40265-023-01866-9
121. [121]
  Y.N. Lamb, S.M. Hoy, Drugs 83 (2023) 807–818. doi: 10.1007/s40265-023-01868-7
122. [122]
  K.A. Lyseng-Williamson, Drugs 77 (2017) 97–106. doi: 10.1007/s40265-016-0679-8
123. [123]
  Y. Yang, M. Zoulikha, Q. Xiao, et al., Acta Pharm. Sin. B 13 (2023) 4607– 4620. doi: 10.1016/j.apsb.2023.05.024
124. [124]
  C.Y. Zhu, F.L. Li, Y.W. Zhang, R.K. Gupta, S.K.S. Patel, J.K. Lee, Polymers 14 (2022) 1409. doi: 10.3390/polym14071409
125. [125]
  A. Radadiya, W. Zhu, A. Coricello, S. Alcaro, N.G.J. Richards, Biochemistry 59 (2020) 3193. doi: 10.1021/acs.biochem.0c00354
126. [126]
  H.K. Ea, P. Richette, Access Rheumatol 4 (2012) 63–70. doi: 10.2147/OARRR.S17431
127. [127]
  I. Iacobucci, B. Hay Mele, F. Cozzolino, et al., Int. J. Mol. Sci. 24 (2023) 4548. doi: 10.3390/ijms24054548
128. [128]
  K.M. Thrailkill, E. Kalaitzoglou, J.L. Fowlkes, Front. Pediatr. 10 (2022) 1012816. doi: 10.3389/fped.2022.1012816
129. [129]
  N. Bouhours-Nouet, C. Teinturier, Arch. Pédiatrie 28 (2022) 8S14–8S20.
130. [130]
  S. Lancellotti, M. Sacco, M. Tardugno, M.E. Mancuso, R. De Cristofaro, Res. Pract. Thromb. Haemost. 7 (2023) 100070. doi: 10.1016/j.rpth.2023.100070
131. [131]
  L.A. Valentino, L. Cong, C. Enockson, et al., Haemophilia 21 (2015) 58–63. doi: 10.1111/hae.12532
132. [132]
  S.L. Meeks, S. Lacroix-Desmazes, Haemophilia 26 (2020) 958–965. doi: 10.1111/hae.14123
133. [133]
  B.A. Konkle, Expert. Rev. Hematol. 16 (2023) 567–573. doi: 10.1080/17474086.2023.2223925
134. [134]
  L. Wang, N. Wang, W. Zhang, et al., Signal Transduct. Target. Ther. 7 (2022) 48. doi: 10.56028/aemr.1.1.48
135. [135]
  J. Li, J. Chen, Q.L. Hu, Z. Wang, X.F. Xiong, Chin. Chem. Lett. (2024), doi: 10.1016/J.CCLET.2024.110126. doi: 10.1016/J.CCLET.2024.110126
136. [136]
  S.M. Hoy, Drugs 81 (2021) 1423–1430. doi: 10.1007/s40265-021-01560-8
137. [137]
  H.M. Salamah, A. Marey, E. Elsayed, et al., Sci. Rep. 13 (2023) 19041. doi: 10.1038/s41598-023-46274-x
138. [138]
  R. Menacho-Melgar, J.S. Decker, J.N. Hennigan, M.D. Lynch, J. Control. Release 295 (2019) 1–12. doi: 10.1016/j.jconrel.2018.12.032
139. [139]
  C. Mathieu, P. Gillard, K. Benhalima, Nat. Rev. Endocrinol. 13 (2017) 385–399. doi: 10.1038/nrendo.2017.39
140. [140]
  E.W. Iepsen, S.S. Torekov, J.J. Holst, Expert Rev. Cardiovasc. Ther. 13 (2015) 753–767. doi: 10.1586/14779072.2015.1054810
141. [141]
  G.A. Christou, N. Katsiki, J. Blundell, G. Fruhbeck, D.N. Kiortsis, Obes. Rev. 20 (2019) 805–815. doi: 10.1111/obr.12839
142. [142]
  Y.Y. Syed, Drugs 82 (2022) 1213–1220. doi: 10.1007/s40265-022-01746-8
143. [143]
  M. Shirley, Drugs 84 (2024) 99–104. doi: 10.1007/s40265-023-01977-3
144. [144]
  M. Sanford, Drugs 74 (2014) 2097–2103. doi: 10.1007/s40265-014-0320-7
145. [145]
  A. Schifferli, F. Nimmerjahn, T. Kühne, Front. Immunol. 10 (2019) 461486.
146. [146]
  M. Muttenthaler, G.F. King, D.J. Adams, P.F. Alewood, Nat. Rev. Drug Discov. 20 (2021) 309–325. doi: 10.1038/s41573-020-00135-8
147. [147]
  Y. Li, K.A. Clark, Z. Tan, Chin. Chem. Lett. 29 (2018) 1074–1078. doi: 10.1016/j.cclet.2018.05.027
148. [148]
  M. Yu, M.M. Benjamin, S. Srinivasan, et al., Adv. Drug Deliv. Rev. 130 (2018) 113. doi: 10.1016/j.addr.2018.07.009
149. [149]
  Y. Li, Y. Wang, Q. Wei, et al., Sci. Rep. 5 (2015) 18039. doi: 10.1038/srep18039
150. [150]
  C. Mathieu, P.J. Martens, R. Vangoitsenhoven, Nat. Rev. Endocrinol. 17 (2021) 715–725. doi: 10.1038/s41574-021-00542-w
151. [151]
  R.M. Poole, M.L. Nowlan, Drugs 74 (2014) 929–938. doi: 10.1007/s40265-014-0228-2
152. [152]
  J.P. Almandoz, I. Lingvay, J. Morales, C. Campos, Clin. Diabetes 38 (2020) 390–402. doi: 10.2337/cd19-0100
1. [1]
  Linghui Zou , Meng Cheng , Kaili Hu , Jianfang Feng , Liangxing Tu . Vesicular drug delivery systems for oral absorption enhancement. Chinese Chemical Letters, 2024, 35(7): 109129-. doi: 10.1016/j.cclet.2023.109129
2. [2]
  Lihang Wang , Mary Li Javier , Chunshan Luo , Tingsheng Lu , Shudan Yao , Bing Qiu , Yun Wang , Yunfeng Lin . Research advances of tetrahedral framework nucleic acid-based systems in biomedicine. Chinese Chemical Letters, 2024, 35(11): 109591-. doi: 10.1016/j.cclet.2024.109591
3. [3]
  Zhilong Xie , Guohui Zhang , Ya Meng , Yefei Tong , Jian Deng , Honghui Li , Qingqing Ma , Shisong Han , Wenjun Ni . A natural nano-platform: Advances in drug delivery system with recombinant high-density lipoprotein. Chinese Chemical Letters, 2024, 35(11): 109584-. doi: 10.1016/j.cclet.2024.109584
4. [4]
  Xingqun Pu , Rongrong Liu , Yuting Xie , Chenjing Yang , Jingyi Chen , Baoling Guo , Chun-Xia Zhao , Peng Zhao , Jian Ruan , Fangfu Ye , David A Weitz , Dong Chen . One-step preparation of biocompatible amphiphilic dimer nanoparticles with tunable particle morphology and surface property for interface stabilization and drug delivery. Chinese Chemical Letters, 2025, 36(3): 109820-. doi: 10.1016/j.cclet.2024.109820
5. [5]
  Jing Zhang , Charles Wang , Yaoyao Zhang , Haining Xia , Yujuan Wang , Kun Ma , Junfeng Wang . Application of magnetotactic bacteria as engineering microrobots: Higher delivery efficiency of antitumor medicine. Chinese Chemical Letters, 2024, 35(10): 109420-. doi: 10.1016/j.cclet.2023.109420
6. [6]
  Tong Tong , Lezong Chen , Siying Wu , Zhong Cao , Yuanbin Song , Jun Wu . Establishment of a leucine-based poly(ester amide)s library with self-anticancer effect as nano-drug carrier for colorectal cancer treatment. Chinese Chemical Letters, 2024, 35(12): 109689-. doi: 10.1016/j.cclet.2024.109689
7. [7]
  Jiaqi Huang , Renjiang Kong , Yanmei Li , Ni Yan , Yeyang Wu , Ziwen Qiu , Zhenming Lu , Xiaona Rao , Shiying Li , Hong Cheng . Feedback enhanced tumor targeting delivery of albumin-based nanomedicine to amplify photodynamic therapy by regulating AMPK signaling and inhibiting GSTs. Chinese Chemical Letters, 2024, 35(8): 109254-. doi: 10.1016/j.cclet.2023.109254
8. [8]
  Minghao Hu , Tianci Xie , Yuqiang Hu , Longjie Li , Ting Wang , Tongbo Wu . Allosteric DNAzyme-based encoder for molecular information transfer. Chinese Chemical Letters, 2024, 35(7): 109232-. doi: 10.1016/j.cclet.2023.109232
9. [9]
  Yong-Dan Zhao , Yidan Wang , Rongrong Wang , Lina Chen , Hengtong Zuo , Xi Wang , Jihong Qiang , Geng Wang , Qingxia Li , Canqi Ping , Shuqiu Zhang , Hao Wang . Reversing artemisinin resistance by leveraging thermo-responsive nanoplatform to downregulating GSH. Chinese Chemical Letters, 2024, 35(6): 108929-. doi: 10.1016/j.cclet.2023.108929
10. [10]
  Keyang Li , Yanan Wang , Yatao Xu , Guohua Shi , Sixian Wei , Xue Zhang , Baomei Zhang , Qiang Jia , Huanhua Xu , Liangmin Yu , Jun Wu , Zhiyu He . Flash nanocomplexation (FNC): A new microvolume mixing method for nanomedicine formulation. Chinese Chemical Letters, 2024, 35(10): 109511-. doi: 10.1016/j.cclet.2024.109511
11. [11]
  Yuanzheng Wang , Chen Zhang , Shuyan Han , Xiaoli Kong , Changyun Quan , Jun Wu , Wei Zhang . Cancer cell membrane camouflaged biomimetic gelatin-based nanogel for tumor inhibition. Chinese Chemical Letters, 2024, 35(11): 109578-. doi: 10.1016/j.cclet.2024.109578
12. [12]
  Yinglan Yu , Sajid Hussain , Jianping Qi , Lei Luo , Xuemei Zhang . Mechanisms and applications: Cargos transport to basolateral membranes in polarized epithelial cells. Chinese Chemical Letters, 2024, 35(12): 109673-. doi: 10.1016/j.cclet.2024.109673
13. [13]
  Zhen Dai , Linzhi Tan , Yeyu Su , Kerui Zhao , Yushun Tian , Yu Liu , Tao Liu . Site-specific incorporation of reduction-controlled guest amino acids into proteins for cucurbituril recognition. Chinese Chemical Letters, 2024, 35(5): 109121-. doi: 10.1016/j.cclet.2023.109121
14. [14]
  Fengjie Liu , Fansu Meng , Zhenjiang Yang , Huan Wang , Yuehong Ren , Yu Cai , Xingwang Zhang . Exosome-biomimetic nanocarriers for oral drug delivery. Chinese Chemical Letters, 2024, 35(9): 109335-. doi: 10.1016/j.cclet.2023.109335
15. [15]
  Yanjing Li , Jiayin Li , Yuqi Chang , Yunfeng Lin , Lei Sui . Tetrahedral framework nucleic acids promote the proliferation and differentiation potential of diabetic bone marrow mesenchymal stem cell. Chinese Chemical Letters, 2024, 35(9): 109414-. doi: 10.1016/j.cclet.2023.109414
16. [16]
  Xinyi Luo , Ke Wang , Yingying Xue , Xiaobao Cao , Jianhua Zhou , Jiasi Wang . Digital PCR-free technologies for absolute quantitation of nucleic acids at single-molecule level. Chinese Chemical Letters, 2025, 36(2): 109924-. doi: 10.1016/j.cclet.2024.109924
17. [17]
  Yujie Li , Ya-Nan Wang , Yin-Gen Luo , Hongcai Yang , Jinrui Ren , Xiao Li . Advances in synthetic biology-based drug delivery systems for disease treatment. Chinese Chemical Letters, 2024, 35(11): 109576-. doi: 10.1016/j.cclet.2024.109576
18. [18]
  Dexuan Xiao , Tianyu Chen , Tianxu Zhang , Sirong Shi , Mei Zhang , Xin Qin , Yunkun Liu , Longjiang Li , Yunfeng Lin . Transdermal treatment for malignant melanoma by aptamer-modified tetrahedral framework nucleic acid delivery of vemurafenib. Chinese Chemical Letters, 2024, 35(4): 108602-. doi: 10.1016/j.cclet.2023.108602
19. [19]
  Ningyue Xu , Jun Wang , Lei Liu , Changyang Gong . Injectable hydrogel-based drug delivery systems for enhancing the efficacy of radiation therapy: A review of recent advances. Chinese Chemical Letters, 2024, 35(8): 109225-. doi: 10.1016/j.cclet.2023.109225
20. [20]
  Yi Cao , Xiaojiao Ge , Yuanyuan Wei , Lulu He , Aiguo Wu , Juan Li . Tumor microenvironment-activatable neuropeptide-drug conjugates enhanced tumor penetration and inhibition via multiple delivery pathways and calcium deposition. Chinese Chemical Letters, 2024, 35(4): 108672-. doi: 10.1016/j.cclet.2023.108672

Get Citation

PDF

XML

Metrics

PDF Downloads(1)
Abstract views(210)
HTML views(13)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142